Your browser doesn't support javascript.
loading
Prebiotic dietary fibre intervention improves fecal markers related to inflammation in obese patients: results from the Food4Gut randomized placebo-controlled trial.
Neyrinck, Audrey M; Rodriguez, Julie; Zhang, Zhengxiao; Seethaler, Benjamin; Sánchez, Cándido Robles; Roumain, Martin; Hiel, Sophie; Bindels, Laure B; Cani, Patrice D; Paquot, Nicolas; Cnop, Miriam; Nazare, Julie-Anne; Laville, Martine; Muccioli, Giulio G; Bischoff, Stephan C; Walter, Jens; Thissen, Jean-Paul; Delzenne, Nathalie M.
Afiliação
  • Neyrinck AM; Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, avenue E. Mounier box B1.73.11, B-1200, Brussels, Belgium.
  • Rodriguez J; Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, avenue E. Mounier box B1.73.11, B-1200, Brussels, Belgium.
  • Zhang Z; Department of Medicine, University of Alberta, Edmonton, Canada.
  • Seethaler B; Institute of Nutritional Medicine, University of Hohenheim, Hohenheim, Germany.
  • Sánchez CR; Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, avenue E. Mounier box B1.73.11, B-1200, Brussels, Belgium.
  • Roumain M; Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, Brussels, Belgium.
  • Hiel S; Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, avenue E. Mounier box B1.73.11, B-1200, Brussels, Belgium.
  • Bindels LB; Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, avenue E. Mounier box B1.73.11, B-1200, Brussels, Belgium.
  • Cani PD; Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, avenue E. Mounier box B1.73.11, B-1200, Brussels, Belgium.
  • Paquot N; WELBIO- Walloon Excellence in Life Sciences and Biotechnology, UCLouvain, Université catholique de Louvain, Brussels, Belgium.
  • Cnop M; Laboratory of Diabetology, Nutrition and Metabolic Disease, Université de Liège, Liège, Belgium.
  • Nazare JA; ULB Center for Diabetes Research, Université Libre de Bruxelles, Brussels, Belgium.
  • Laville M; Division of Endocrinology, Erasmus Hospital, Université Libre de Bruxelles, Brussels, Belgium.
  • Muccioli GG; Rhône-Alpes Research Center for Human Nutrition, Université-Lyon, CarMeN Laboratory, Hospices Civils de Lyon, Lyon, France.
  • Bischoff SC; Rhône-Alpes Research Center for Human Nutrition, Université-Lyon, CarMeN Laboratory, Hospices Civils de Lyon, Lyon, France.
  • Walter J; Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, Brussels, Belgium.
  • Thissen JP; Institute of Nutritional Medicine, University of Hohenheim, Hohenheim, Germany.
  • Delzenne NM; Department of Medicine, University of Alberta, Edmonton, Canada.
Eur J Nutr ; 60(6): 3159-3170, 2021 Sep.
Article em En | MEDLINE | ID: mdl-33544206
ABSTRACT

PURPOSE:

Inulin-type fructans (ITF) are prebiotic dietary fibre (DF) that may confer beneficial health effects, by interacting with the gut microbiota. We have tested the hypothesis that a dietary intervention promoting inulin intake versus placebo influences fecal microbial-derived metabolites and markers related to gut integrity and inflammation in obese patients.

METHODS:

Microbiota (16S rRNA sequencing), long- and short-chain fatty acids (LCFA, SCFA), bile acids, zonulin, and calprotectin were analyzed in fecal samples obtained from obese patients included in a randomized, placebo-controlled trial. Participants received either 16 g/d native inulin (prebiotic n = 12) versus maltodextrin (placebo n = 12), coupled to dietary advice to consume inulin-rich versus inulin-poor vegetables for 3 months, in addition to dietary caloric restriction.

RESULTS:

Both placebo and prebiotic interventions lowered energy and protein intake. A substantial increase in Bifidobacterium was detected after ITF treatment (q = 0.049) supporting our recent data obtained in a larger cohort. Interestingly, fecal calprotectin, a marker of gut inflammation, was reduced upon ITF treatment. Both prebiotic and placebo interventions increased the ratio of tauro-conjugated/free bile acids in feces. Prebiotic treatment did not significantly modify fecal SCFA content but it increased fecal rumenic acid, a conjugated linoleic acid (cis-9, trans-11 CLA) with immunomodulatory properties, that correlated notably to the expansion of Bifidobacterium (p = 0.031; r = 0.052).

CONCLUSIONS:

Our study demonstrates that ITF-prebiotic intake during 3 months decreases a fecal marker of intestinal inflammation in obese patients. Our data point to a potential contribution of microbial lipid-derived metabolites in gastro-intestinal dysfunction related to obesity. CLINICALTRIALS. GOV IDENTIFIER NCT03852069 (February 22, 2019 retrospectively, registered).
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Prebióticos / Inulina Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: Eur J Nutr Assunto da revista: CIENCIAS DA NUTRICAO Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Prebióticos / Inulina Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: Eur J Nutr Assunto da revista: CIENCIAS DA NUTRICAO Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Bélgica